Anaveon is a biotechnology company specializing in the development of pharmaceutical products, particularly immunotherapies. The company's core activity encompasses the research and development of therapeutic candidates, ranging from discovery to clinical testing. Anaveon focuses on treating immune-mediated diseases and has expertise in the areas of autoimmunity, transplantation, and inflammation.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
✓ Offered5
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of precision biologics, engineered antibodies and cytokine-based therapies to selectively modulate the immune system in autoimmune and inflammatory diseases.
Immunology pipeline
Development of immunology programs focused on ANV200 and additional pipeline candidates to eliminate or reprogram pathogenic immune cells.
ANV200
PD-1-depleting antibody in preclinical development for autoimmune diseases; intended to deeply deplete pathogenic T cells and reset inflammatory immune responses.
Collaboration and partnerships
Licensing, co-development or acquisition for the oncology portfolio, as well as partnering inquiries for the further development of selected programs.
Oncology portfolio
Legacy oncology assets with ANV600, ANV700 and other preclinical or clinical programs; focus on development and potential partnerships.